Pomaglumetad methionil did not separate from placebo in the primary efficacy endpoint in either the overall or predefined genetic subpopulation at the two doses investigated (40mg and 80mg BID).
Risperidone, the active control, did separate from placebo in both the populations, the study reported.
Lilly Research Laboratories president and science and technology executive vice president Jan Lundberg said unfortunately negative studies are common in the field of psychiatry and a reality of biopharmaceutical innovation.
"Right now, we’re developing more than a half dozen potential new medicines to treat neuroscience-related diseases and disorders, including among others, depression, Alzheimers disease and schizophrenia," Lundberg added.
Pomaglumetad methionil was well tolerated in general, with no new safety findings compared to previous trials.